{"pub": "morningstar", "url": "https://morningstar.com/news/dow-jones/201910235470/alexion-3q-net-profit-rises-raises-full-year-guidance", "downloaded_at": "2019-10-23 12:17:12.190407+00:00", "title": "Alexion 3Q Net Profit Rises; Raises Full-Year Guidance", "language": "en", "text": "By Carlo Martuscelli\n\nAlexion Pharmaceuticals Inc. on Wednesday reported a 41% increase in third-quarter profit and raised its full-year guidance.\n\nThe New Haven, Conn.-based drug maker earned a quarterly profit of $467.6 million, or $2.08 a share, compared with $330.9 million, or $1.47, for the same period last year. Excluding items, Alexion reported an adjusted profit of $2.79 a share for the quarter, compared with $2.02 last year and analyst forecasts of $2.48.\n\nSales rose to $1.26 billion from $1.03 billion, it added.\n\nChief Executive Ludwig Hantson said that the company had benefited from a very rapid launch of Ultomiris in Germany and Japan. The drug is a treatment for paroxsymal nocturnal hemoglobinuria, a rare blood-disease.\n\nAlexion raised its revenue guidance for 2019 to between $4.86 billion and $4.89 billion, from $4.75 billion to $4.8 billion. It now sees adjusted EPS in the range of $10.25 to $10.40, up from $9.65 to $9.85 which it guided for previously.\n\nWrite to Carlo Martuscelli at carlo.martuscelli@dowjones.com; @carlomartu\n\n(END) Dow Jones Newswires\n\nOctober 23, 2019 07:09 ET (11:09 GMT)\n\nCopyright (c) 2019 Dow Jones & Company, Inc.", "description": "", "authors": [], "top_image": "https://morningstar.com/assets/img/30241a1.png", "published_at": "2019-10-23"}